01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported a third quarter of 2025 with product revenues, net, of $142.3 milliona, up $48.9 million, or 52.4%, from $93.4 million a year earlier.
The increase reflects $28.1 millionb of US sales of BRINSUPRI, the company's second commercial product, which received FDA approval on August 12, 2025, and 22.3% growth in global ARIKAYCE sales. Operating expenses rose sharply: SG&A increased 56.7% to $186.4 million, driven by commercial readiness for BRINSUPRI, and R&D increased 23.6% to $186.4 million. A $104.7 million non-cash charge from the change in fair value of deferred and contingent consideration, attributed mainly to the higher share price, contributed to a net loss of $370.0 million for the quarter, or $(1.75) per share, compared with a net loss of $220.5 million, or $(1.27) per share, in the prior-year quarter.
For the nine months ended September 30, 2025, the net loss was $948.3 millionc. The balance sheet was strengthened by financing activity. The company completed an underwritten offering of 8,984,375 shares at $96.00 per share in June 2025, with net proceeds of $823.3 million, and its 0.75% convertible senior notes were redeemed in June 2025 after holders converted most of them into common stock.
At September 30, 2025, the company held $334.8 milliond in cash and cash equivalents and $1,345.2 million in marketable securities, with working capital of $1.5 billion. Term loans of $500.0 million principal bear a fixed 9.6% rate and mature September 30, 2029. Net cash used in operating activities was $687.4 million for the nine months.
Management states that current funds are sufficient to meet financial needs for at least the next 12 months, while noting it may raise additional capital. Near-term catalysts include topline data from the BiRCh trial of brensocatib in chronic rhinosinusitis without nasal polyps, expected by early January 2026; topline data from the ENCORE trial of ARIKAYCE and from the CEDAR trial of brensocatib in hidradenitis suppurativa, both expected in the first half of 2026; and a planned Phase 3 TPIP study in PAH in early 2026.
The filing also notes that the CHMP adopted a positive opinion for BRINSUPRI in October 2025. Customer concentration is significant: for the nine months ended September 30, 2025, three customers accounted for 30%, 26% and 21% of gross product revenue.
02—Key points
Key Highlights
- Q3 2025 product revenues, net, rose 52.4% to $142.3 million, including $28.1 million of first-quarter US BRINSUPRI sales following its August 2025 FDA approval.
- Net loss widened to $370.0 million ($1.75 per share) in Q3 2025 from $220.5 million ($1.27 per share), largely due to a $104.7 million charge from the change in fair value of deferred and contingent consideration liabilities and higher SG&A.
- SG&A expenses increased 56.7% to $186.4 million in Q3 2025, mainly from professional fees and headcount tied to BRINSUPRI commercial activities.
- The June 2025 equity offering raised $823.3 million in net proceeds; cash and cash equivalents were $334.8 million and marketable securities $1,345.2 million at September 30, 2025.
- The 2028 convertible notes were redeemed on June 6, 2025, and term loans of $500.0 million principal carry a fixed 9.6% rate with a September 30, 2029 maturity.
- Key pipeline readouts expected in early 2026 include BiRCh (CRSsNP) by early January, ENCORE (ARIKAYCE) and CEDAR (HS) in the first half of 2026.
- Three customers accounted for 30%, 26% and 21% of gross product revenue for the nine months ended September 30, 2025, indicating concentration.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $142.34M$93.42M | +52.4% |
| Cost of Revenue | $29.36M$21.17M | +38.7% |
| Gross Profit | $112.98M$72.25M | +56.4% |
| R&D Expenses | $186.41M$150.81M | +23.6% |
| SG&A Expenses | $186.38M$118.93M | +56.7% |
| Operating Expenses | $508.35M$306.85M | +65.7% |
| Operating Income | -$366.00M-$213.43M | −71.5% |
| Net Income | -$370.02M-$220.52M | −67.8% |
| EPS (Basic) | $-1.75$-1.27 | −37.8% |
| EPS (Diluted) | $-1.75$-1.27 | −37.8% |
| Shares Outstanding (Basic) | 211.76M173.72M | +21.9% |
| Shares Outstanding (Diluted) | 211.76M173.72M | +21.9% |
05—Questions
Frequently Asked Questions
How did revenue perform in the third quarter of 2025?
Product revenues, net, were $142.3 million, up $48.9 million, or 52.4%, from $93.4 million in the third quarter of 2024. US BRINSUPRI sales contributed $28.1 million, and global ARIKAYCE sales grew 22.3%, with international sales up 51.8%.
Why did the net loss increase so much?
The net loss was $370.0 million in Q3 2025 versus $220.5 million a year earlier. The filing attributes the increase mainly to a $104.7 million change in fair value of deferred and contingent consideration liabilities, primarily due to the increase in the share price, along with higher SG&A (up $67.4 million) and R&D (up $35.6 million) expenses.
Does the company have enough cash to fund operations?
The company had $334.8 million in cash and cash equivalents and $1,345.2 million in marketable securities at September 30, 2025, and working capital of $1.5 billion. Management states it has sufficient funds for at least the next 12 months but may raise additional capital in the future.
What debt does the company have outstanding?
Term loans with $500.0 million principal, bearing a fixed 9.6% rate, mature September 30, 2029, with repayments starting January 3, 2028. The 0.75% convertible senior notes due 2028 were redeemed in June 2025, and the royalty financing agreement with OrbiMed carried a carrying value of $163.9 million.
What upcoming events could affect the stock?
The company expects topline data from the BiRCh trial of brensocatib in CRSsNP by early January 2026, and from the ENCORE trial of ARIKAYCE and the CEDAR trial of brensocatib in HS in the first half of 2026. It also plans to start a Phase 3 PAH study of TPIP in early 2026 and expects EU, UK and Japan regulatory decisions for brensocatib, with commercial launches anticipated in 2026 pending approval.
06—Continue